drugset
drugset / Trial / NCT07057089

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

NCT07057089 ↗

Phase 2 Recruiting 90 enrolled Hebei Medical University Fourth Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the efficacy and safety of involved-field radiotherapy-TNT combined with PD-1 inhibitors in pMMR locally advanced rectal cancer.

Timeline

Start
2025-07-01
Primary completion
2028-03-01
Completion
2030-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg —
Background Capecitabine Small molecule 825 mg/m2 Oral

Indications

No indication recorded.